Skip to main content
. 2021 Aug 4;13:6101–6111. doi: 10.2147/CMAR.S319650

Figure 4.

Figure 4

The subgroup analysis of different treatment patterns for BM patients at baseline. (A) iPFS and (B) OS of CRT alone group and CRT + anlotinib group for patients with different treatment patterns.